Journal of Clinical Oncology and Cancer Research

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Reach Us +1 (629)348-3199

Research Article - Journal of Clinical Oncology and Cancer Research (2018) Volume 1, Issue 1

Cyclin D1 immunohistochemical expression in Sudanese patients affected with prostatic carcinoma in Khartoum state.

Prostatic carcinoma is a common public health problem in aging people. Cyclin D1 proto-oncogene is an important regulator of G1 to S phase progression in many different cell types, It is believed to play an important role in both tumorigenesis and grading of many cancers including prostatic carcinoma; high levels of these proteins have been reported in certain human malignancies and have been implicated in aberrant cell division and dysregulated tumor growth. The aims of this study were to examine the immunohistochemical expression of Cyclin D1 in prostatic carcinoma and to demonstrate the association or relation between Cyclin D1 expressions and to determine the aggressiveness of the malignant tumors by Gleason Score. In this study 50 samples, 25 cases of prostatic cancer and 25 cases benign prostatic tissues were studied for Cyclin D1 expression using an immunohistochemical technique which was performed on routinely processed, formalin fixed and paraffin embedded tissues; then tissues were sectioned into thickness of (3 µm to 5 µm) with rotary microtome instrument and immunohistochemical expression of CyclinD 1 was evaluated in all cases. All of the primary human prostatic cancer samples revealed in different ranges of intensity from weak (+1), moderate (+2) to strongly positive nuclear staining (+3) for Cyclin D1. In this study we revealed no nuclear staining in the benign prostatic hyperplasia (PBH) disease (+0) in 21 cases (84%) and 4 cases (16%) were ranged in different color intensity; 3 (12%) were weak (1+) and 1 (4%) case was moderate (2+) while prostatic cancer cases were also evaluated in different colors; 13 cases (52%) were (+3), 7cases (28%) were (+2) and 3 cases were (12%) were (+1) and only two (8%) were negative. There was no significance correlation between Gleason's score and intensity of Cyclin D1 expression. Conclusively we can say that Cyclin D1 may be helpful in the differentiation between BPH and prostate cancer, the correlation between the intensity of Cyclin D1 expression and prostatic diseases was statistically highly significant (p value=0.00).We recommended to use Cyclin D1 as a biomarker to prostatic carcinoma.

Author(s): Muaid Ali Obeid Hadi, Albadawi abdelbagi Talha, Ali Seed Ahmed, Abdairaheem Ali Babiker

Abstract Full Text PDF

Get the App